Nucleic Acid Encapsulation Service for Targeted Delivery

The realization of precision medicine hinges on the ability to safely and accurately deliver delicate genetic payloads to specific cellular targets. Nucleic Acid Targeted Delivery Services bridge the critical gap between groundbreaking genomic research and transformative commercial applications. By overcoming inherent biological barriers, enzymatic degradation, and the limitations of traditional systemic administration, we ensure that your therapeutics arrive intact and perform flawlessly at the designated site of action. Creative Biolabs' unparalleled expertise in engineering intelligent, cell-specific lipid and polymer-based delivery vehicles empowers researchers to turn complex nucleic acid concepts into viable, life-changing realities.

Request a Free Scientific Consultation

Conquering Biological Barriers for Precision Medicine

To fully leverage the potential of gene therapy and targeted interventions, researchers must address several highly complex pharmacokinetic and cellular hurdles. We break down the science of nucleic acid delivery into a logical, four-stage progression:

The Core Problem: The Inherent Vulnerability of Nucleic Acids

Before addressing how to deliver a payload, we must understand why nucleic acids (siRNA, mRNA, plasmid DNA, and CRISPR-Cas9 RNPs) are notoriously difficult to administer in their "naked" form.

• High Molecular Weight & Negative Charge: Cell membranes are naturally negatively charged lipid bilayers. The strong negative charge and large size of nucleic acids prevent them from passively crossing this membrane.
• Enzymatic Degradation: The bloodstream is rich in nucleases (enzymes that cleave RNA and DNA) designed to destroy foreign genetic material, leading to rapid degradation of unprotected therapeutic payloads.

Our specialized services support a range of therapeutic nucleic acids.

Plasmid DNA (pDNA)

Properties: Large, circular double-stranded DNA structure (5–15 kbp).
Target Site: Nucleus

Messenger RNA (mRNA)

Properties: Single-stranded linear transcript derived from DNA.
Target Site: Cytosol

Small Interfering RNA (siRNA)

Properties: Short, double-stranded RNA sequence (typically 21–25 bp).
Target Site: Cytosol

MicroRNA (miRNA)

Properties: Endogenous, short noncoding double-stranded RNA.
Target Site: Nucleus

sgRNA (CRISPR guide RNA)

Properties: Short, noncoding RNA sequence complexed with Cas proteins.
Target Site: Nucleus

Antisense Oligonucleotides (ASO)

Properties: Chemically stabilized, short single-stranded DNA/RNA analogs.
Target Site: Cytosol / Nucleus

The Journey: Navigating the Three-Tiered Biological Barricade

Once a nucleic acid is introduced into the body, it must survive a perilous journey to its intracellular target. A successful delivery vehicle must overcome three distinct bottlenecks:

• 1. Systemic Circulation & Immune Clearance: The carrier must evade the reticuloendothelial system (RES) and macrophages, preventing premature clearance from the bloodstream while avoiding an adverse immunogenic response.
• 2. Cellular Internalization: Upon reaching the target tissue, the carrier must successfully bind to the cell surface and trigger endocytosis (cellular engulfment).
• 3. Endosomal Escape (The Critical Bottleneck): Once inside the cell, the payload is trapped in an acidic vesicle called an endosome. If the delivery system cannot rupture this endosome quickly, the nucleic acid will be trafficked to a lysosome and destroyed.

Fig. 1 The biological barriers of the nucleic acid delivery systems (NADS) in vivo.^1,3

The Complexity of Formulation: Four Pillars of Delivery System Design

Designing a vector that successfully navigates the biological barricades is highly nuanced. At Creative Biolabs, our formulation scientists carefully optimize four critical parameters to ensure the clinical success of your targeted therapy:

Fig. 2 Materials and strategies for targeted RNA delivery.^2,3

• 1. Category of Vector Materials: The foundational choice of carrier, ranging from lipid-based (LNPs, liposomes) and polymeric vectors to inorganic materials or exosomes. This selection dictates the carrier's baseline safety profile, payload capacity, and inherent immunogenicity.
• 2. Chemical Structures of Vectors: The precise molecular architecture is important. For instance, the tail length of a lipid, the degree of branching in a polymer, or the exact pKa of an ionizable group will dictate how efficiently the vector binds the nucleic acid and releases it in response to intracellular pH changes.
• 3. Physicochemical Properties of Vectors: Macroscopic characteristics such as particle size (typically 50-150 nm for ideal cellular uptake), zeta potential (surface charge affecting stability and toxicity), and morphological shape must be rigorously controlled to ensure proper biodistribution and tissue penetration.
• 4. Administration Routes: The intended clinical route (e.g., Intravenous, Intramuscular, Subcutaneous, or Inhalation) drastically alters the pharmacokinetic barriers the vector will face. Formulations must be uniquely engineered to survive the specific physiological environment of the injection site.

Creative Biolabs provides a suite of engineered solutions tailored to your unique payload and biological target. To ensure maximum precision and efficacy, we deploy two primary strategies for nucleic acid delivery:

• Carrier-Based Delivery Systems: Encapsulating the fragile nucleic acid payload within an advanced vehicle (e.g., LNPs, liposomes, exosomes) that is often decorated with specific targeting ligands to navigate biological barriers.
• Direct Ligand-Nucleic Acid Conjugation: Covalently linking the "naked" nucleic acid (e.g., siRNA, ASO) directly to a targeting moiety (e.g., GalNAc, aptamers, peptides) for precise, carrier-free cellular uptake.

Based on these core strategies, we offer the following specialized services:

Nucleic Acid Synthesis Ligand Discovery Carrier Development Direct Conjugation

Nucleic Acid Payload Design & Synthesis

Before delivery, the therapeutic cargo itself must be optimized for stability, efficacy, and minimal immunogenicity. We offer comprehensive design and synthesis services for various nucleic acid modalities, ensuring your payload is primed for successful targeted delivery.

• Sequence Optimization: Utilizing advanced bioinformatics tools to optimize codon usage and minimize secondary structures that could impede translation or silencing.
• Chemical Modification: Incorporating modified nucleotides (e.g., pseudouridine, 2'-O-methyl) to enhance nuclease resistance and evade immune detection in systemic circulation.
• Scalable Synthesis: Providing high-yield, high-purity synthesis of mRNA, siRNA, ASOs, and custom guide RNAs from research to preclinical scales.

Targeting Ligand Design, Screening & Validation

Achieving true extrahepatic delivery relies on the high-affinity binding of targeting ligands to specific cell-surface receptors. Our dedicated ligand discovery team provides end-to-end services, from in silico design to rigorous in vitro validation, ensuring your delivery vehicle acts with pinpoint precision.

• Rational Ligand Design: Employing computational modeling to design custom aptamers, cell-penetrating peptides (CPPs), and small molecule targeting moieties.
• High-Throughput Screening: Utilizing phage display and in vitro selection technologies to rapidly identify ligands with the highest binding affinity and specificity for your target receptor.
• Receptor Binding Validation: Conducting rigorous in vitro assays (e.g., Flow Cytometry, Surface Plasmon Resonance) to confirm ligand-receptor interactions and cellular internalization rates.

Carrier-Based Nucleic Acid Targeted Delivery

We utilize advanced vector systems to encapsulate and protect your fragile nucleic acid payloads, navigating biological barriers to achieve precise cellular delivery. While Lipid Nanoparticles (LNPs) serve as our flagship and most clinically advanced carrier, our expertise extends to liposomes, polymeric nanoparticles, exosomes, and hybrid vectors tailored to your specific payload.

• Microfluidic LNP Engineering: Utilizing high-throughput microfluidic mixing to create uniform, low-polydispersity lipid nanoparticles with custom ionizable lipids for optimal endosomal escape.
• Exosome-Based Carriers: Harnessing highly biocompatible, naturally derived extracellular vesicles for targeted delivery, providing an exceptional safety profile and endogenous stealth capabilities.
• Polymeric & Hybrid Vectors: Designing biodegradable polymeric systems (e.g., PEI, PLGA) or lipid-polymer hybrids when specific release kinetics or massive payload capacities are required.
• Vector Optimization: Iteratively screening and adjusting component molar ratios to maximize encapsulation efficiency (EE%) and optimize for specific administration routes (IV, IM, SubQ).

Direct Ligand-Nucleic Acid Conjugation

For specific payloads that do not require full encapsulation, we offer precision covalent conjugation to active targeting moieties. This carrier-free strategy minimizes the overall molecular footprint while maintaining high tissue specificity, making it particularly effective for robust siRNA and ASO therapeutics.

• GalNAc-Conjugation: Engineering highly efficient, targeted hepatocyte delivery systems using optimized triantennary GalNAc structures for siRNA and ASOs.
• Aptamer & Peptide Conjugation: Covalently linking nucleic acids to custom aptamers or cell-penetrating peptides (CPPs) to facilitate robust extrahepatic cellular uptake.
• Linker Chemistry Optimization: Selecting and optimizing linker types (cleavable vs. non-cleavable) to ensure stability in circulation and controlled intracellular payload release.

Case Study

Workflow

Cross-Disciplinary Applications of Targeted Delivery Technologies

While originally pioneered for human therapeutics, our advanced Nucleic Acid Targeted Delivery Services are highly adaptable platforms driving innovation across multiple scientific industries.

• Precision Oncology & Gene Therapy: Enabling the precise delivery of CRISPR-Cas9 components and siRNA to solid tumors while sparing healthy tissues, drastically improving the therapeutic window.
• Agrigenomics & Crop Protection: Delivering RNA interference (RNAi) molecules to targeted agricultural pests or specific plant tissues to enhance crop resilience without the use of broad-spectrum chemical pesticides.
• Veterinary Therapeutics: Developing advanced mRNA vaccines and targeted gene therapies for the prevention and treatment of complex diseases in livestock and companion animals.
• Advanced Cosmeceuticals: Utilizing functionalized liposomes for the deep, targeted delivery of bioactive peptides and nucleic acids into specific dermal layers for anti-aging and skin repair applications.
• Biomanufacturing & Synthetic Biology: Precisely modifying production cell lines by delivering plasmids and gene-editing tools to enhance the yield of recombinant proteins and valuable biologics.

Creative Biolabs stands at the forefront of biochemical engineering, providing the definitive tools and expertise necessary to conquer the challenges of systemic administration and cellular targeting. Whether you are delivering a novel mRNA therapeutic to the lungs, a gene editor to a specific tumor microenvironment, or an agricultural RNAi to a plant system, our bespoke Nucleic Acid Targeted Delivery Services ensure your payload arrives safely, stably, and effectively.

Related Services & Products

Related Services

Functionalized Liposome Development Services

Bioconjugation Services

Targeted Module Synthesis Services

Chemical Synthesis Services

Analytical & Characterization Service

Nucleic Acid Synthesis Services

Payload Encapsulation Services

Related Products

FAQs

References

1. Ye, Mengyun, et al. "Effect of the size of nucleic acid delivery systems on their fate in cancer treatment." Exploration of Drug Science 2.1 (2024): 38-49.https://doi.org/10.37349/eds.2024.00035.
2. Lin, Lixin, et al. "Targeting materials and strategies for RNA delivery." Theranostics 13.13 (2023): 4667. https://doi.org/10.7150/thno.87316.
3. Distributed under Open Access license CC BY 4.0, without modification.